Prosecution Insights
Last updated: November 17, 2026
Application No. 16/629,309

BIOACTIVE COATING FOR SURFACE ACOUSTIC WAVE SENSOR

Non-Final OA §103§112
Filed
Jan 07, 2020
Priority
Jul 07, 2017 — provisional 62/529,986 +3 more
Examiner
CHIN, CHRISTOPHER L
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aviana Molecular Technologies LLC
OA Round
8 (Non-Final)
81%
Grant Probability
Favorable
8-9
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
580 granted / 719 resolved
+20.7% vs TC avg
Strong +23% interview lift
Without
With
+22.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
22 currently pending
Career history
741
Total Applications
across all art units

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/24/26 has been entered. Claims 22, 23, 26, 28, 31, 33-35, and 84-93 are being prosecuted. Claims 48 and 51 are withdrawn. Claim Rejections - 35 USC § 112 3. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 4. Claims 22, 23, 26, 28, 31, 33-35, and 84-93 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The specification, as originally filed, does not provide support for the biosensor of amended claim 22. Claim 22 now recites an anchor substance that comprises a spacer and a binding component, wherein the spacer comprises a polymer linker with a silane at one end and a biotin moiety on the other end. Thus, the anchor substance comprises: silane group – spacer – biotin - binding component, wherein the binding component binds to a capture reagent. The binding component would then need to have an avidin attached to it so it can bind to the biotin on the spacer and also have a component that can bind to the capture reagent. The specification does not appear to teach such an anchor substance. The instant specification teaches an anchor substance that comprises a polymer linker with a silane on end and a binding component that binds to a capture reagent. Page 5, lines 16-23, of the specification teaches a spacer coupled to a binding component where a biotinylated capture reagent binds to the binding component on the spacer. Here the binding component is probably avidin. Page 8, lines 16-22, and page 9, lines 13-19, of the specification teaches the same structure for the anchor substance. The instant specification does not provide support for the anchor substance that is not recited in claim 22. This is a new matter rejection. 5. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. 6. Claim 93 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 93 does not recite any limitations at all that would further limit the biosensor of claim 22. Furthermore, there are no limitations that would make the biosensor of claim 22 a “bulk wave resonator”. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 7. The 103 rejections based on Shih et al (US 2010/0068490) in view of Morton et al (US 2017/0017872) and further in view of Hashimoto et al (US 2004/0013794) are withdrawn in view of Applicant’s amendments and arguments. 8. The 103 rejections based on Rivas et al (US 2017/0117871) in view of Shih et al (US 2010/0068490) withdrawn in view of Applicant’s amendments and arguments. Allowable Subject Matter 9. Claims 22, 23, 26, 28, 31, 33-35, and 84-93 are free of the prior art of record. The closest prior art is Su et al (US 2005/0164236) which teaches a piezoelectric resonator biosensor comprising a quartz oscillator with a metal layer thereon. An analyte specific capture molecule can be attached to the metal layer with an anchor substance comprising a spacer having a functional group that binds to the metal layer at one end and biotin at the other end. A binding component (second spacer molecule) such as avidin can also be employed which can bind to the biotin on the spacer molecule and to a biotinylated capture molecule ([0055] – [0058]). However, Su et al fails to teach the spacer being a polymer linker with a silane group at one end as the functional group and the metal surface being plasma-activated. Conclusion 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L CHIN whose telephone number is (571)272-0815. The examiner can normally be reached Monday - Friday, 10:00am - 6:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy Nguyen can be reached at 571-272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTOPHER L CHIN/Primary Examiner, Art Unit 1677 9/30/2026
Read full office action

Prosecution Timeline

Show 15 earlier events
Aug 15, 2024
Request for Continued Examination
Aug 16, 2024
Response after Non-Final Action
Jul 15, 2025
Non-Final Rejection mailed — §103, §112
Oct 15, 2025
Response Filed
Feb 24, 2026
Final Rejection mailed — §103, §112
Aug 24, 2026
Request for Continued Examination
Aug 25, 2026
Response after Non-Final Action
Oct 02, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12775006
METHOD FOR ISOLATING A TARGET FROM A SAMPLE
5y 7m to grant Granted Oct 27, 2026
Patent 12758973
Micro-Fluidic System Using Micro-Apertures for High Throughput Detection of Cells
5y 2m to grant Granted Oct 13, 2026
Patent 12742776
METHOD AND SYSTEM FOR EVALUATION OF AN INTERACTION BETWEEN AN ANALYTE AND A LIGAND USING A BIOSENSOR
4y 8m to grant Granted Sep 22, 2026
Patent 12698518
PROCESS OF DIRECTLY DETECTING AND IDENTIFYING A MICROORGANISM IN A BIOLOGICAL SAMPLE DILUTED IN AN ENRICHMENT BROTH
5y 7m to grant Granted Aug 04, 2026
Patent 12699086
MODIFIED ELISA WITH HEMOGLOBIN CORRECTION APPARATUS AND METHODS THEREOF
3y 3m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

8-9
Expected OA Rounds
81%
Grant Probability
99%
With Interview (+22.6%)
High
PTA Risk
Based on 719 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month